MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
MYRIAD GENETICS INC
NASDAQ:MYGN (11/21/2024, 5:20:01 PM)
After market: 15.12 0 (0%)15.12
-0.18 (-1.18%)
Company Profile
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
Company Info
MYRIAD GENETICS INC
322 North 2200 West
Salt Lake City UTAH 84108
P: 18015843600
CEO: R. Bryan Riggsbee
Employees: 2700
Website: https://myriad.com/
MYGN News
a day ago - Myriad Genetics, Inc.Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types
a day ago - Myriad Genetics, Inc.Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2....
2 days ago - Myriad Genetics, Inc.Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy2 days ago - Myriad Genetics, Inc.Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into PregnancyMyriad Genetics announced Prequel® Prenatal Screen is now available at eight weeks into pregnancy....
7 days ago - Bronstein, Gewirtz & Grossman, LLCMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm8 days ago - Bronstein, Gewirtz & Grossman, LLCMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc....
MYGN Twits
Here you can normally see the latest stock twits on MYGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
